Resiliency Roadmap Update: US FDA Exceeds FY 2021 Inspection Projections
While better than one its ‘best case’ scenarios, FDA has completed just 31% of 15,514 domestic surveillance inspections planned for FY 2021, applications are still being delayed, and foreign inspections have for the most part yet to be tackled.
You may also be interested in...
The “Accord for a Healthier World” pledges to provide patent-protected medicines on a not-for-profit basis in 45 lower-income nations. Pfizer, which profited most from the COVID-19 pandemic, sees the pandemic experience as a way to advance health equity.
Agency’s Office of Regulatory Affairs mines third-country EU inspections and remotely delivered documents while investing travel savings, redirecting field force and preparing for new post-pandemic travel challenges.
Robert Califf’s first tenure as US FDA Commissioner was decidedly anti-climactic. His return trip – assuming the Senate confirms him – will be potentially transformational: he will be the leader that defines what FDA is after COVID.